Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Atea Pharmaceuticals Inc AVIR

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 (COVID-19). It is... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (NDAQ:AVIR)

Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference

GlobeNewswire 4 hours ago

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024

GlobeNewswire 11 days ago

Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire November 7, 2024

Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

GlobeNewswire October 31, 2024

Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024

GlobeNewswire October 30, 2024

Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19

GlobeNewswire September 13, 2024

Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir's Metabolic Activation Pathway

GlobeNewswire August 28, 2024

Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire August 7, 2024

Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024

GlobeNewswire July 31, 2024

Opinion & Analysis (NDAQ:AVIR)

No current opinion is available.

Bullboard Posts (NDAQ:AVIR)

6 REASONS TO AVOID ATEA PHARMACEUTICALS ($AVIR)

6 REASONS TO AVOID ATEA PHARMACEUTICALS ($AVIR) https://www.aviseanalytics.com/6-reasons-to-avoid-atea-pharmaceuticals/ Atea...
AviseAnalytics - November 19, 2021

AVIR - Friday Rundown, Monday Expectations

<< View Post To Watch Video >>
HDavis - October 31, 2021

RE:Bonvoyage12....Pathetic Pumper

India's Ivermectin Blackout - Part V: The Secret Revealed ...   Sep 27, 2021 · By September 12, 2021...
zeropointenergy - October 6, 2021

Bonvoyage12....Pathetic Pumper

This pumper spams multiple boards with paid PR BS......depserately trying to promote losing stocks....ignore him and report him.
Mil_Man54 - December 1, 2020